| Date | Title | | | December 14, 2015 | Incyte to Present at the 34th Annual J. P. Morgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 14, 2015--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the 34th Annual J. P. Morgan Healthcare Conference on Monday,
January 11, 2016 at 1:30 p.m. PST (4:30 p.m. EST) in San Francisco.
The presentation will be webcast live and can be accessed within the
Investors section of www.incyte.com
under Events and Presentations. Investors interested in listening to the
live webcas... |
|  | | December 05, 2015 | Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint| Patients with polycythemia vera without enlarged spleen treated with
Jakafi achieved hematocrit control without phlebotomy
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 5, 2015--
Incyte Corporation (Nasdaq:INCY) announces the Phase 3 RESPONSE-2 study
of Jakafi® (ruxolitinib) met its primary endpoint. Treatment
with Jakafi achieved hematocrit control without the need for phlebotomy
in patients with inadequately controlled polycythemia vera (PV)
resi... |
| | | December 05, 2015 | Two Phase 3 Studies Reinforce Sustained Benefits of Treatment with Jakafi® (ruxolitinib) in Patients with Myeloproliferative Neoplasms (MPNs)| COMFORT-II data demonstrate that patients with myelofibrosis treated
with Jakafi achieved a 33 percent reduction in the risk of death after
five years
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 5, 2015--
Incyte Corporation (Nasdaq:INCY) announces data from two Phase 3 studies
evaluating the long-term safety and efficacy of Jakafi®
(ruxolitinib) in patients with Myeloproliferative Neoplasms (MPNs). In
myelofibrosis (MF), results of a five-year fol... |
| | | November 30, 2015 | Incyte’s Jakafi® (ruxolitinib) to be Featured in over 60 Abstracts at ASH Annual Meeting| Five-year COMFORT-II data in myelofibrosis and multiple ruxolitinib
combination studies in MPNs and other hematologic malignancies accepted
as oral and poster presentations
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 30, 2015--
Incyte Corporation (Nasdaq:INCY) announces that more than 60 abstracts
featuring data from its ongoing clinical development program for Jakafi®
(ruxolitinib) will be presented at the upcoming American Society of
Hematology ... |
| | | November 07, 2015 | Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate | INDIANAPOLIS, Nov. 7, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monotherapy in helping patients achieve clinical remission. Findings will be shared at the American College of Rheumatology /Association of Rheumatology Health Professionals annual meeting in San Francisco, reveali... |
| | | November 07, 2015 | Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis| Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab
Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab
Detailed results from pivotal phase 3 study RA-BEAM presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting
PR Newswire, Indianapolis, November 7, 2015
Eli Lilly and... |
| | | November 03, 2015 | Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers| Combination of IDO1 inhibitor plus PD-1 antagonist demonstrates
responses and disease control in a broad range of tumor types and is
generally well-tolerated with low rates of Grade 3 or higher adverse
events
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 3, 2015--
Incyte Corporation (Nasdaq:INCY) announces the first presentation of
findings from the ongoing proof-of-concept Phase 1/2 study evaluating
epacadostat, Incyte’s selective IDO1 inhibitor, i... |
| | | November 03, 2015 | Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| - $161 million of 2015 third-quarter net product revenues from Jakafi®
(ruxolitinib), representing 65 percent growth over the same period last
year
- Positive results from two pivotal trials of baricitinib to be
highlighted at ACR; baricitinib superior to both methotrexate (RA-BEGIN)
and to Humira® (adalimumab) (RA-BEAM) in
reducing the signs and symptoms of rheumatoid arthritis
- Agreement announced with Merck to expand clinical c... |
| | | October 14, 2015 | Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study| INDIANAPOLIS, Oct. 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
The study met its primary objective of demonstrating superiority compared to placebo after 12 weeks of treatment based on ACR20 response – a standard clinical measure that repre... |
| | | October 13, 2015 | Incyte to Report Third Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 13, 2015--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its third quarter 2015 financial results conference call and webcast for
10:00 a.m. ET on Tuesday, November 3, 2015.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | October 13, 2015 | Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma| Pivotal study to evaluate Incyte’s IDO1 inhibitor in combination with
Merck’s anti-PD-1 therapy in patients with advanced or metastatic
melanoma
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Oct. 13, 2015--
Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD
outside the United States and Canada, today announced the expansion of
the companies’ ongoing clinical collaboration to include a Phase 3 study
evaluat... |
| | | October 02, 2015 | Data at SITC Annual Meeting to Highlight Progress of Incyte’s Immuno-oncology Portfolio| Results of a proof-of-concept study of epacadostat, Incyte’s IDO1
inhibitor, in combination with pembrolizumab to be presented as a
late-breaking abstract
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 2, 2015--
Incyte Corporation (Nasdaq:INCY) announces that new data from its
investigational immuno-oncology portfolio will be presented at the
upcoming Society for Immunotherapy of Cancer (SITC) 30th Anniversary
Annual Meeting & Associated Programs... |
| | | September 29, 2015 | Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis| INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response ra... |
| | | September 15, 2015 | Incyte to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 15, 2015--
Incyte Corporation (Nasdaq: INCY) announced today it will present at the
Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on
Thursday, October 1, 2015 at 3:15 p.m. (EDT) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. Investors interested in
listening to the live webcast should log on before th... |
| | | September 10, 2015 | MPN Awareness Day Raises Awareness and Support for the Nearly 300,000 People in the United States Affected by Rare Blood Cancers | September 10, 2015, commemorates the third annual MPN Awareness Day
Incyte supports MPN awareness by providing patient resources and programs throughout September
Call for MPN Heroes™ Recognition Program Nominations Ends Today
WILMINGTON, Del.--(BUSINESS WIRE)--September is Blood Cancer Awareness Month and, today, the MPN Coalition, a group of seven patient advocacy organizations, recognizes MPN Awareness Day. MPN Awareness Day, September 10... |
| | | September 02, 2015 | Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody| Incyte to pay Hengrui $25 million upfront plus the potential for
milestone and royalty payments
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 2, 2015--
Incyte Corporation (Nasdaq: INCY) today announced a global license and
collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the
development and commercialization of SHR-1210, an investigational
anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the
exclusive developme... |
| | | September 01, 2015 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 1, 2015--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of September:
Morgan Stanley 2015 Global Healthcare Conference on Thursday,
September 17, 2015 at 12:20 pm (EDT) in New York; and
Bank of America Merrill Lynch Global Healthcare Conference 2015 on
Thursday, September 17, 2015 at 1:45 pm (BST) in Lo... |
| | | August 21, 2015 | Incyte Named 7th Most Innovative Company in the World by Forbes Magazine| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 21, 2015--
Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company focused
on the discovery, development and commercialization of innovative
proprietary therapeutics, today announced it has been ranked 7th on
Forbes magazine’s 2015 list of the World’s Most Innovative
Companies.
Forbes’ ranking is based on the companies’ “innovation premium”,
and only includes industries that are known to inves... |
| | | August 04, 2015 | Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| $142 million of 2015 second-quarter net product revenues from Jakafi®
(ruxolitinib), representing 69 percent growth over the
same period last year
2015 guidance for Jakafi net product revenues increased to range of
$560 million to $575 million, driven by strong underlying demand
Positive results from two pivotal trials of baricitinib in
rheumatoid arthritis presented at EULAR
Multiple a... |
| | | July 14, 2015 | Incyte to Report Second Quarter Financial Results on August 4| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2015--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its second quarter 2015 financial results conference call and webcast
for 10:00 a.m. ET on Tuesday, August 4, 2015. The schedule for the press
release and conference call/webcast is as follows:
... |
| | | July 07, 2015 | Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance| Agreement to collaborate on basic and translational research to
enable novel therapeutic approaches for patients with cancer
Incyte to provide financial support for the grant-based research
program, which has an initial collaboration period of three years,
with the option to extend
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 7, 2015--
Incyte Corporation (Nasdaq: INCY) today announced that it has entered
into... |
| | | June 19, 2015 | Incyte Announces Organizational and Management Changes to Drive Future Global Expansion| Jim Daly, EVP and Chief Commercial Officer, to leave Incyte at end
of June, for personal reasons
Dr. Barry Flannelly, appointed EVP and General Manager U.S., to
lead regional operating team for United States
Incyte to establish Global Product Strategy and BD&L unit to
strategically manage growing portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 19, 2015--
Incyte Corporation (Nasdaq: INCY) ... |
| | | June 10, 2015 | Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis| EULAR congress in Rome will be first public presentations of Phase 3 data
INDIANAPOLIS, June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in Rome June 10-13. Lilly and Incyte prev... |
| | | May 28, 2015 | Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data| INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will be presented on June 11 during the Scientific Programme for the EULAR Congress 2015 in Rome, Italy.
The webcast will be held from 10:00 to11:00 a.m. Eastern Daylight Time. The live audio webcast... |
| | | May 27, 2015 | Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings| Results from ongoing proof-of-concept trial of PI3Kδ inhibitor
INCB40093 as monotherapy and in combination with JAK1 inhibitor
INCB39110 in B-cell malignancies, including Hodgkin lymphoma
Follow-up results from pivotal RESPONSE trial of ruxolitinib in
patients with uncontrolled polycythemia vera, showing 83% of patients
were still receiving ruxolitinib at a median exposure of 111 weeks
WILMINGTON, Del.--(BUSINESS WIR... |
| | | April 30, 2015 | Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| $115 million of 2015 first-quarter net product revenues from Jakafi®
(ruxolitinib), representing 66 percent growth over the same period
last year
$25 million milestone received from Novartis related to the
approval of Jakavi® (ruxolitinib) for
polycythemia vera in Europe; $16 million product royalties from sales
of Jakavi, representing 60 percent growth over the same period last
year
Primary e... |
| | | April 23, 2015 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 23, 2015--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of May:
Deutsche Bank Securities 40th Annual Health Care Conference
on Thursday, May 7, 2015 at 10:00 am (EDT) in Boston;
Bank of America Merrill Lynch 2015 Health Care Conference on Thursday,
May 14, 2015 at 8:00 am (PDT) in Las Vegas; and
... |
| | | April 17, 2015 | Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting| Live discussion, presentation and webcast to be held on April 20th
Incyte's FGFR, BRD and PIM inhibitor programs described
Clinical trials of FGFR inhibitor underway; BRD inhibitor expected
to enter clinical development during second quarter 2015
Immuno-therapeutic activity of JAK and PI3Kδ inhibitors highlighted
Potential for combination strategies within and across both
targete... |
| | | April 14, 2015 | Incyte to Report First Quarter Financial Results on April 30| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2015--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its first quarter 2015 financial results conference call for 8:00 a.m.
ET on Thursday, April 30, 2015. The schedule for the press release and
conference call is as follows:
... |
| | | April 14, 2015 | Incyte to Establish European Headquarters in Geneva, Switzerland| New facility to serve as European base for Incyte’s drug
development operations
Location provides efficient access to key clinical trial experts
and institutions
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2015--
Incyte Corporation (Nasdaq:INCY) today announced that it will establish
the new headquarters of Incyte Europe S.a.r.l (“Incyte Europe”) in
Geneva, Switzerland. Incyte intends to use Incyte Europe as the b... |
| | | March 17, 2015 | Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera| WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2015--
Incyte Corporation (Nasdaq: INCY) announced today that Novartis received
approval from the European Commission for Jakavi®
(ruxolitinib) for the treatment of adult patients with polycythemia vera
(PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the
first targeted treatment approved by the European Commission for these
patients.
Under the Incyte-Novartis Collaboration and L... |
| | | March 02, 2015 | Incyte Appoints Steven H. Stein, MD as Chief Medical Officer| WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2015--
Incyte Corporation (Nasdaq: INCY) announced today that Steven H. Stein,
MD, has been appointed Senior Vice President and Chief Medical Officer,
effective immediately. Dr. Stein was formerly SVP, US Clinical
Development & Medical Affairs at Novartis Oncology US, and he will be
responsible for clinical and medical strategy and operations across
Incyte’s extensive oncology portfolio.
Steve... |
| | | February 26, 2015 | Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer| Results expected to provide better strategies for both patients and
physicians to manage the burden of this disease
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 26, 2015--
Incyte Corporation (Nasdaq: INCY) today announced that it is sponsoring
the first major observational study of patients living with polycythemia
vera (PV) in the U.S. PV is a rare and progressive blood cancer that can
lead to debilitating symptoms, serious cardiovascular complications, ... |
| | | February 23, 2015 | Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study| INDIANAPOLIS, Feb. 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional ... |
| | | February 17, 2015 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 17, 2015--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of March:
Cowen and Company 35th Annual Health Care Conference on
Tuesday, March 3, 2015 at 10:40 am (EST) in Boston; and
Barclays Global Healthcare Conference on Wednesday, March 11, 2015 at
3:50 pm (EDT) in Miami
The prese... |
| | | February 12, 2015 | Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs| $106 million of 2014 fourth-quarter net product revenues from Jakafi®
(ruxolitinib), representing 46 percent growth over the same period
last year
$358 million of 2014 full-year net product revenues from Jakafi,
representing 52 percent growth over last year
2015 guidance for Jakafi net product revenues in the range of $525
million to $565 million, reflecting continued growth in underlying
demand in mye... |
| | | January 28, 2015 | Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine| Data show Jakafi® (ruxolitinib) was
superior to standard therapy; resulting in durable hematocrit control,
spleen volume reduction and complete hematological remission in
patients with uncontrolled polycythemia vera (PV)1
PV is a rare blood cancer associated with overproduction of blood
cells that can cause serious cardiovascular complications, such as
stroke and heart attack2
Jakafi® was recently appr... |
| | | January 27, 2015 | Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2015--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter 2014 financial results conference call for 8:30 a.m.
ET on Thursday, February 12, 2015. The schedule for the press release
and conference call is as follows:
... |
| | | January 23, 2015 | Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 23, 2015--
Incyte Corporation (Nasdaq: INCY) today announced that it has earned a
$25 million milestone payment from Novartis. This payment was triggered
by the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) adopting a positive opinion for Jakavi®
(ruxolitinib) for the treatment of adult patients with polycythemia vera
(PV) who are resistant to or intolerant of hydroxyu... |
| | | January 09, 2015 | Incyte Board Appoints Two New Directors| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 9, 2015--
Incyte Corporation (Nasdaq: INCY) today announced the appointment of
Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin
Pharmaceutical Inc., and Paul J. Clancy, Executive Vice President,
Finance and Chief Financial Officer of Biogen Idec Inc., as new
Directors. The appointments are effective January 20, 2015.
“The Incyte board welcomes Jean-Jacques and Paul as their extensive and
re... |
| | | January 09, 2015 | Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies| Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3
Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies
Agenus to receive $60 million comprised of a $25 million technology and program access fee under the collaboration plus $35 million equity investment in Agenus at $4.51/share
Agenus eligible to receive up to $350 million in development, regulatory and commercial... |
| |
|
